CoChat

Alzheimer’s disease: where next for anti-amyloid therapies?

Open access
Hardy, John, De Strooper, Bart · 2017 · Brain
Cited by 67

The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.

Abstract

The recent failures of the solanezumab Expedition 3 and the verubecestat phase II/III trials to significantly slow disease progression in mild or mild-to-moderate Alzheimer’s disease are considerable disappointments. They are causing soul searching in the field: are we on the right track and what do we need to do to get effective mechanistic therapies? While there have been previous trial failures of anti-amyloid therapies, most of these had clear problems during their preclinical development, which perhaps should have allowed their failure to be foreseen (Karran and Hardy, 2014). The solanezumab trial, in contrast, had been approached with cautious optimism in the light of the marginally positive data on clinical slowing in mild disease in secondary analyses of the earlier Expedition and Expedition 2 trials (Doody et al., 2014). Verubecestat appeared to be a safe and effective BACE-1 inhibitor (Kennedy et al., 2016) allowing effective amyloid-β lowering in the CNS. Thus both approaches appeared to have overcome most of the shortcomings encountered in previous trials although the fact that biomarker confirmation of Alzheimer pathology was not required in the verubecestat trial was a clear shortcoming. In addition, the two approaches are complementary as they hit the amyloid-β peptide from either the clearance side (solanezumab) or from the production side (verubecestat). Thus, these were two serious tests of the amyloid hypothesis, and, in practical clinical terms, both turned out negative. With the repetitive failing of trials, it is time to reconsider the 25-year-old amyloid cascade hypothesis (Selkoe and Hardy, 2016) and the clinical equivalent data summarized in the ‘Jack curves’ (Jack and Holtzman, 2013). Both imply a linear relationship between the amyloid-β pathology and neuronal cell death and dementia. Dementia is, however, the clinical manifestation of a much more complex process not only involving neurons, but also strong other cellular reactions from microglia, astroglia, oligodendrocytes and vasculature. Dementia may not be a direct consequence of amyloid-β toxicity but instead as the result of a decade long disease process called the ‘cellular phase’ of Alzheimer’s disease (De Strooper and Karran, 2016). Genetic evidence for this complexity comes from the identification of microglial response genes as risk loci for Alzheimer’s disease (Matarin et al., 2015). At a theoretical level, the negative outcome of anti-amyloid therapy was not excluded, even without putting the causal contribution of amyloid-β to Alzheimer’s disease into question (Karran et al., 2011). In one disease scenario, amyloid-β was proposed as a driver of the disease process. If this would be the case, any lowering of amyloid-β would slow disease progression. This possibility is ruled out by the failed clinical trials. In another scenario (Karran et al., 2011), amyloid-β has to reach a certain threshold to cause harm. If amyloid-β therapy is not able to lower the amyloid-β level in the brain below that threshold, then no beneficial effects of anti-amyloid drugs would be expected. In the third scenario, amyloid-β is proposed to be only a trigger of the disease process (Karran et al., 2011). If this is the case, then amyloid-β directed drugs would have no effect at all after the disease process has been initiated. It looks like the failed trials are consistent with both the threshold and the trigger scenarios. The alternative possibility that amyloid-β is an entirely innocent bystander of the disease process is unlikely as it is not reconcilable with genetic evidence that mutations in APP are sufficient to cause Alzheimer’s disease. More detailed analysis of the solenezumab trial data is possible because they were made entirely available by Eli-Lilly. ADAS-Cog scores showed tiny improvements, in the same direction as the trends in the earlier solanezumab trials (Siemers et al., 2016). For example, in mild Alzheimer’s disease, the improvement in ADAS-Cog over 80 weeks on drug was 44% in Expedition, 20% in Expedition 2 but only 11% in Expedition 3 (P = 0.095). These data overall may suggest some small influence of amyloid-β lowering on disease progression. We have to wait until all data from the verubecestat trail are made available to see whether a similar weak positive signal was captured there. What do the results mean for other amyloid-β antibody approaches? The next up is aducanumab. This targets plaque rather than soluble amyloid-β and has been shown to remove plaques in imaging studies (Sevigny et al., 2016). This is indeed an interesting approach. However, although there is a sense of optimism about this, a potential concern is that bapineuzumab also partially cleared plaques, albeit in the context of amyloid-related imaging abnormalities, without evidence for clinical utility (Holmes et al., 2008). This imperfect precedent argues that simple clearance is not the answer. Also, much has been made of the correlation between p

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/brain/awx059

Cites

13 of 13 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 13 references

Cited by

Metadata

Authors
Hardy, J., & De Strooper, B.
Venue
Brain
Published
2017-03-25
Volume
140
Issue
4
Pages
853-855
ISSN
  • 0006-8950 (ISSN-L)
  • 1460-2156
OpenAlex
W2603633491
Cited by
67
References
13
FWCI
6.35
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.